Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Neomorph, Inc
Bristol-Myers Squibb
Xencor, Inc.
Baylor College of Medicine
Nuvectis Pharma, Inc.
Arcus Biosciences, Inc.
M.D. Anderson Cancer Center
Pfizer
Tizona Therapeutics, Inc
Dana-Farber Cancer Institute
HiberCell, Inc.
Novartis
Kura Oncology, Inc.
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
AstraZeneca
Coherus Oncology, Inc.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Genentech, Inc.
DEKA Biosciences
University of Iowa
Columbia University
Five Eleven Pharma, Inc.
Molecure S.A.
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Inhibrx Biosciences, Inc
Taiho Oncology, Inc.
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celldex Therapeutics
Case Comprehensive Cancer Center
AO GENERIUM
Aurigene Discovery Technologies Limited
Corvus Pharmaceuticals, Inc.
Lisata Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Canadian Cancer Trials Group
AvenCell Therapeutics, Inc.
Dana-Farber Cancer Institute
Janssen Research & Development, LLC
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Imperial College London
Syndax Pharmaceuticals
Pfizer